NUCRYST Pharma (NCST) Appoints Interim CEO
More News related to NCST
- NUCRYST Announces Special Meeting of Shareholders
- Westaim announces 2009 third quarter results
- NUCRYST announces 2009 third quarter financial results
- Unusual 11 Mid-Day Movers 11/11: NCST, SMI, MSN, CHLN Higher; TONE, RHIE, CLWR, STV Lower
- Notable Mergers and Acquisitions of the Day 11/11: BIN/WSII, NCST/SNN, SYK/SURG, LOGI/LifeSize
More News related to Management Changes
- Top 10 News Items 11/23-11/27: Dubai Debt Fallout; Gold; GDP Revised Lower; Diedrich Coffee Bidding War
- Trading Radar for 11/30: Inergy Holdings (NRGP), Golar (GLNG), Omnivision (OVTI), Knightsbridge (VLCCF) Report
- Notable Mergers and Acquisitions of the Day for 11/27: F, S/IPCS, STAR/CSCO, HRAY
- Notable Analyst Rating Changes 11/27: TIF, QLTI Upgraded; FSNM, RGFC Downgraded
- Notable ETF Movers *Special Dubai World Edition* 11/27: UUP Higher; GAF, EEM, FXI, XLF Lower
The Board of Directors of NUCRYST Pharmaceuticals Corp. (Nasdaq: NCST) announced the appointment of David B. Holtz as interim President and Chief Executive Officer of the Company and Neil Carragher as Chairman, effective immediately. Mr. Holtz replaces Thomas E. Gardner, who was Chairman, President and Chief Executive Officer. Mr. Carragher, currently lead director of NUCRYST, will assume the role of Chairman, effective immediately. Mr. Holtz will also remain as CFO.
Previously, Mr. Holtz was Vice President and Chief Financial Officer of NUCRYST.
Subscribe to EasyStockAlerts.com & Get real-time e-mail alerts when news hits your stocks!
NUCRYST Pharmaceuticals Corp. (NASDAQ: NCST; TSX: NCS) develops, manufactures and commercializes medical products that fight infection and inflammation using SILCRYST(TM).
Related Categories
Management ChangesStocks Mentioned
+0.01Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
